These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 7914157)

  • 1. Responsiveness of T lymphocytes from systemic lupus erythematosus to signals provided through CD26 antigen.
    Plana M; Font J; Viñas O; Martorell J; Ingelmo M; Vives J
    Clin Immunol Immunopathol; 1994 Aug; 72(2):227-32. PubMed ID: 7914157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.
    Martorell J; Font J; Rojo I; Vilella R; Ingelmo M; Vives J
    Clin Exp Immunol; 1989 Nov; 78(2):172-6. PubMed ID: 12412744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phorbol myristate acetate (PMA) reverses inhibition of interleukin-2 production by T lymphocytes of patients with systemic lupus erythematosus.
    Sierakowski S; Kucharz EJ
    Med Interne; 1988; 26(1):67-73. PubMed ID: 3261032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immobilized anti-CD5 together with prolonged activation of protein kinase C induce interleukin 2-dependent T cell growth: evidence for signal transduction through CD5.
    Vandenberghe P; Ceuppens JL
    Eur J Immunol; 1991 Feb; 21(2):251-9. PubMed ID: 1705509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective CD2 pathway T cell activation in systemic lupus erythematosus.
    Fox DA; Millard JA; Treisman J; Zeldes W; Bergman A; Depper J; Dunne R; McCune WJ
    Arthritis Rheum; 1991 May; 34(5):561-71. PubMed ID: 1673843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of interleukin 2 (IL 2) and interferon-gamma and enhancement of IL 2 receptor expression by a CD26 monoclonal antibody.
    Plana M; Viñas O; De la Calle-Martin O; Lozano F; Inglés-Esteve J; Romero M; Alberola-Ila J; Yagüe J; Vilella R; Vives J
    Eur J Immunol; 1991 Apr; 21(4):1085-8. PubMed ID: 1673434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of IL-10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus.
    González-Amaro R; Portales-Pérez D; Baranda L; Abud-Mendoza C; Llorente L; Richaud-Patin Y; Alcocer-Varela J; Alarcón-Segovia D
    J Autoimmun; 1998 Oct; 11(5):395-402. PubMed ID: 9802922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.
    Tanaka T; Kameoka J; Yaron A; Schlossman SF; Morimoto C
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4586-90. PubMed ID: 7685106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation.
    Bednarczyk JL; Carroll SM; Marin C; McIntyre BW
    J Cell Biochem; 1991 Jul; 46(3):206-18. PubMed ID: 1723066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocytes from patients with systemic lupus erythematosus show increased response to interleukin-2 after costimulation with OKT3 monoclonal antibody and phorbol esters.
    Blasini AM; Stekman IL; Gonzalez F; Tositti ML; Rodriguez MA
    Clin Immunol Immunopathol; 1994 Jan; 70(1):66-72. PubMed ID: 8261671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus.
    Stekman IL; Blasini AM; Leon-Ponte M; Baroja ML; Abadi I; Rodriguez MA
    Arthritis Rheum; 1991 Apr; 34(4):459-67. PubMed ID: 1826426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD26 monoclonal antibodies can reversibly arrest human T lymphocytes in the late G1 phase of the cell cycle.
    Mattern T; Ansorge S; Flad HD; Ulmer AJ
    Immunobiology; 1993 Jun; 188(1-2):36-50. PubMed ID: 8104880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus.
    Portales-Pérez D; González-Amaro R; Abud-Mendoza C; Sánchez-Armáss S
    Lupus; 1997; 6(1):48-56. PubMed ID: 9116719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low responsiveness to the anti Leu 4 antibody by T cells from patients with active systemic lupus erythematosus.
    Kaneoka H; Morito F; Yamaguchi M
    J Clin Lab Immunol; 1989 Jan; 28(1):15-26. PubMed ID: 2470907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired T-cell activation in patients with systemic lupus erythematosus.
    Sierakowski S; Kucharz EJ; Lightfoot RW; Goodwin JS
    J Clin Immunol; 1989 Nov; 9(6):469-76. PubMed ID: 2517125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for the involvement of three distinct signals in the induction of IL-2 gene expression in human T lymphocytes.
    June CH; Ledbetter JA; Lindsten T; Thompson CB
    J Immunol; 1989 Jul; 143(1):153-61. PubMed ID: 2543699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas (CD95)-transduced signal preferentially stimulates lupus peripheral T lymphocytes.
    Sakata K; Sakata A; Vela-Roch N; Espinosa R; Escalante A; Kong L; Nakabayashi T; Cheng J; Talal N; Dang H
    Eur J Immunol; 1998 Sep; 28(9):2648-60. PubMed ID: 9754553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate.
    Murakawa Y; Sakane T
    Arthritis Rheum; 1988 Jul; 31(7):826-33. PubMed ID: 3260781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes.
    Turka LA; Ledbetter JA; Lee K; June CH; Thompson CB
    J Immunol; 1990 Mar; 144(5):1646-53. PubMed ID: 2155264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of cord T lymphocytes. II. Cellular and molecular analysis of the defective response induced by anti-CD3 monoclonal antibody.
    Bertotto A; Gerli R; Lanfrancone L; Crupi S; Arcangeli C; Cernetti C; Spinozzi F; Rambotti P
    Cell Immunol; 1990 May; 127(2):247-59. PubMed ID: 2139363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.